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OBJECTIVES: To investigate the effect of metabolic syn-
drome on cognitive function in an elderly Latino population
and to determine whether inflammation modifies this asso-
ciation.
DESIGN: A longitudinal cohort study.
SETTING: Sacramento area and the surrounding Califor-
nia counties from 1998 to 1999.
PARTICIPANTS: One thousand six hundred twenty-four
Latinos aged 60 and older who participated in the Sacra-
mento Area Latino Study of Aging.
MEASUREMENTS: Baseline metabolic syndrome was
calculated using the Third Adult Treatment Panel of the
National Cholesterol Education Program. Cognitive func-
tion was measured using the Modified Mini-Mental State
Examination (3MS) and the Delayed Word-List Recall
(DelRec), a verbal memory test. The effect of metabolic
syndrome on cognitive change scores was examined using
random effects models; in addition, the effect of the indi-
vidual components of the syndrome on cognitive change
was examined.
RESULTS: Of the 1,624 participants, 718 (44%) had met-
abolic syndrome at baseline. Those with metabolic syn-
drome had worse 3-year change scores on 3MS (P 5.04)
and DelRec (P 5.03). Multivariate adjustment attenuated
the results for DelRec but not for 3MS. This association was
especially pronounced in participants with a high serum
level of inflammation, resulting in an average 3MS score
0.64 points lower per year (P 5.03) for those with meta-
bolic syndrome. Individual components of metabolic syn-
drome were not associated with cognitive decline except for
elevated glucose on the DelRec (P 5.02) and high blood
pressure on 3MS (P 5.05).
CONCLUSION: Metabolic syndrome and inflammation
may both contribute to cognitive decline in older people of
diverse backgrounds. The results also suggest that, in elder-
ly Latinos, the composite measure of metabolic syndrome
is a greater risk for cognitive decline than its individual
components. J Am Geriatr Soc 55:758–762, 2007.
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Metabolic syndrome is a constellation of cardiovascu-lar risk factors that include abdominal obesity, hy-
pertriglyceridemia, low high-density lipoprotein (HDL)
levels, hypertension, and hyperglycemia1 and is associated
with greater risk of developing diabetes mellitus and
cardiovascular disease. Although several of these cardio-
vascular and metabolic risk factors have been independ-
ently associated with a greater risk of developing dementia
or cognitive decline, the effect of metabolic syndrome
on cognitive function has not been extensively studied.
It was recently demonstrated that metabolic syndrome
contributes to cognitive impairment in older black and
white people, particularly in those with high levels of
inflammation.2
By 2005, Hispanic Americans are estimated to become
the largest ethnic minority group in the United States.3 This
is especially significant because older Hispanic people have
a high prevalence of diabetes mellitus and metabolic syn-
drome,4 although few studies have examined the effects of
this higher prevalence on cognitive outcomes. The present
study was conducted to investigate the effect of metabolic
syndrome on cognitive function in an elderly Hispanic
population and to determine whether inflammation mod-
ified this association. As part of an ongoing prospective
study, whether metabolic syndrome was associated with
cognitive decline in older people without dementia was
determined.
The Sacramento Area Latino Study of Aging (SALSA)
study was an ideal cohort in which to address this question,
because the participants were all older community-dwelling
Latinos who had careful characterization of metabolic
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syndrome and inflammation and were prospectively followed
with cognitive assessments. The hypothesis was that pres-
ence of metabolic syndrome would be associated with




SALSA participants were recruited from the Sacramento
area and the surrounding California counties from 1998 to
1999. A detailed description of the study and recruitment
has been described elsewhere.4 In brief, participants were
eligible for enrollment if they were aged 60 and older and
self-designated as Latino. Bilingual technicians performed
annual interviews in the primary language of the participant
at the participant’s home. Of the 1,789 participants initially
enrolled, 1,624 with data on metabolic syndrome and cog-
nitive function constituted the analytical cohort. This anal-
ysis covers the period from baseline to the third annual
follow-up visit.
The institutional review boards of the University of
California at Davis and the University of California at San
Francisco approved the study, and written informed con-
sent was obtained from all participants.
Measurements
Baseline metabolic syndrome was calculated using the
Third Adult Treatment Panel of the National Cholesterol
Education Program.1 Participants were considered to have
metabolic syndrome if they met three or more of five
criteria: abdominal obesity (waist circumference 488 cm
for women;4102 cm for men), hypertriglyceridemia
(150 mg/dL),3 low HDL cholesterol (o40 mg/dL for
men;o50 mg/dL for women), high blood pressure (systolic
130 mmHg, diastolic85 mmHg) or use of antihyperten-
sive medication, and high fasting blood glucose (110 mg/
dL) or use of antidiabetic medication.
At baseline, fasting blood was collected from each par-
ticipant and stored at 701C at the University of California
at Davis. High-sensitivity C-reactive protein (CRP) was
analyzed at the University of Michigan CLASS laboratory
using the Equal Diagnostics high-sensitivity CRP kit
(Exton, PA). Inflammation level was dichotomized at the
median level (3.2 mg/L), which is similar to the American
Heart Association and Centers for Disease Control and
Prevention recommended cutoff of 3.0 mg/L.
Cognitive function was measured using the Modified
Mini-Mental State Examination (3MS) and the Delayed
Word-List Recall (DelRec) from the Spanish-English verbal
learning test. These measurements were collected at base-
line and each year postbaseline. The 3MS is a global mea-
sure of cognitive functioning, with components for
orientation, concentration, language, praxis, and immedi-
ate and delayed recall; scores range from 0 to 100, with
higher scores representing better cognition.5 The DelRec is
a test of short-term verbal memory; scores range from 0 to
15, with higher scores representing better functioning.6
Both tests were validated in Spanish and English.
At baseline, information was gathered on participants’
age, sex, education (years), primary language, country of
birth, and current smoking and alcohol use. Report of a
physician diagnosis of stroke or myocardial infarction (MI)
was gathered from the participant at each visit. Depressive
symptoms were assessed using the Center for Epidemiologic
Studies Depression Scale.7 The standard of 16 or more de-
pressive symptoms was used to define presence of depres-
sion. The Acculturation Rating Scale for Latinos was used
to measure acculturation.8
Statistical Analyses
Comparisons of baseline characteristics of those with and
without metabolic syndrome were performed using t tests
for normally distributed continuous variables, Wilcoxon
rank-sum tests for those with skewed distributions, and chi-
square tests for categorical data. Transformations on both
cognitive tests were necessary to meet the normality as-
sumption of the models used. The DelRec was transformed
using  (DelRec Score11); the 3MS was transformed using
Log(Log((3MS score)/10110.001)). All results were
backtransformed for presentation.
Random-effects models were used to analyze the asso-
ciation between the presence of metabolic syndrome at
baseline and the 3-year change in cognitive functioning as
measured using the 3MS and the DelRec. These models
account for between-participant variation and within-par-
ticipant correlation of repeated outcomes.9 The random-
effect terms included the intercept and the slope of the
cognitive measurements over time, allowing for individual time
trends for each participant. Variances and covariances were
estimated using the restricted maximum likelihood method.
Time was modeled as a continuous covariate, measured as
years from baseline. The covariates (fixed effects) were de-
termined using backward selection with a Po.10 selection
criterion. If a variable was selected for the 3MS or the
DelRec model, it was kept in both models, for consistency.
The results presented are beta coefficients and P-values for the
predictor, which represent the baseline difference between
mean cognitive scores of those with metabolic syndrome and
those without, and the beta coefficients and P-values for the
interaction term of time and the predictor, which represents
the difference over time in mean cognitive scores between
those with metabolic syndrome and those without.
Similar analyses were performed using the five individ-
ual components of metabolic syndrome as predictors, with
separate models for each component to assess whether the
effect of the individual components differed from the effect
of metabolic syndrome. Analyses were also performed after
stratifying participants according to their CRP level (3.2
vso3.2 mg/L). Analyses were preformed using SAS (version
9.1, SAS Institute, Inc., Cary, NC).
RESULTS
The mean age  standard deviation of the whole cohort
was 70.5  7.0. Of the 1,624 participants, 718 (44%) had
metabolic syndrome at baseline. Of those, 593 (83%) had
abdominal obesity, 573 (80%) had hypertriglyceridemia,
419 (58%) had low HDL cholesterol, 164 (23%) had high
blood pressure or were taking antihypertensive medication,
and 473 (66%) had high fasting blood glucose or were
taking antidiabetic medication. Those with metabolic syn-
drome were more likely to be female, to have been born in
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the United States, to be depressed, and to have a history of
stroke or MI than those without metabolic syndrome
(Po.05) (Table 1). Those with metabolic syndrome were
less likely to be high school educated or to be current
smokers (P 5.4) and consumed less alcohol (Po.05). There
was no significant difference in age, primary language, or
acculturation between the two groups. As expected, par-
ticipants with metabolic syndrome had higher mean levels
of CRP than those without the syndrome (Po.001).
Mean baseline cognitive function was 84.6  14.1
using the 3MS and 8.4  3.2 using the DelRec. The aver-
age follow-up time was 2.6  1.3 years, with 65% of the
analysis population having cognitive data gathered through
Year 3. The reasons for lack of follow-up include death
(n 5 120), refusal (n 5 142), lost to follow-up (n 5 137),
had follow-up but no cognitive testing (n 5 77), and still
followed but did not have testing within the timeframe of
the return visit (n 5 91). The proportion of participants
with baseline presence of metabolic syndrome or elevated
CRP level did not differ for those with and without follow-
up. For the entire cohort, the repeated-measures model in-
dicated no significant difference in baseline cognitive scores
for those with and without metabolic syndrome for the
3MS or the DelRec (Tables 1 and 2), although those with
metabolic syndrome had greater decline on the 3MS
(P 5.04) and on the DelRec (P 5.03) (Table 2). After multi-
variate adjustment for age, sex, education, place of birth,
depression, history of stroke, MI, smoking, and alcohol
use, those with metabolic syndrome scored 0.39 points
lower per year on the 3MS than those without metabolic
Table 1. Baseline Characteristics of Sacramento Area Latino Study of Aging Participants with and without Metabolic
Syndrome
Characteristic
Without Metabolic Syndrome With Metabolic Syndrome
P-value(n 5 906) (n 5 718)
Age, mean  SD 70.8  7.3 70.2  6.6 .10
Female, n (%) 480 (53.0) 470 (65.5) o.001
Education high school, n (%) 296 (32.7) 195 (27.2) .02
Born in the United States, n (%) 427 (47.1) 385 (53.6) .01
Primary language is English, n (%) 401 (44.3) 306 (42.6) .51
Depression, n (%) 202 (22.9) 194 (27.4) .04
History of stroke, n (%) 62 (6.8) 88 (12.3) o.001
History of myocardial infarction, n (%) 52 (5.7) 90 (12.5) o.001
Alcohol (drinks per week), mean  SD 3.1  8.8 1.5  6.5 o.001
Current smoker, n (%) 117 (12.9) 70 (9.8) .04
Acculturation score (range 0–60), mean  SD 22.5  12.9 22.0  13.1 .37
C-reactive protein, mg/L, mean  SD 4.8  7.2 6.8  9.4 o.001
Modified Mini-Mental State Examination score, mean  SD 84.8  14.0 84.3  14.2 .39
Delayed Word-List Recall score, mean  SD 8.4  3.2 8.4  3.1 .89
Center for Epidemiological Studies Depression Scale score 16.
SD 5 standard deviation.
Table 2. Association Between Metabolic Syndrome and Cognitive Change: Unadjusted and Multivariate-Adjusted Ran-
dom-Effects Model
Model
Modified Mini-Mental State Examination Score Delayed Word-List Recall Score
Metabolic Syndrome
Metabolic Syndrome
by Time Metabolic Syndrome
Metabolic Syndrome
by Time
Beta P-value Beta P-value Beta P-value Beta P-value
Unadjusted
All  0.41 .44  0.35 .04 0.07 .67  0.12 .03
CRPmedian  0.23 .78  0.46 .04  0.18 .51  0.13 .16
CRPomedian  0.69 .41  0.20 .45  0.13 .65  0.06 .45
Multivariate adjusted
All  0.29 .56  0.39 .04  0.12 .38  0.07 .17
CRPmedian 0.43 .61  0.64 .03  0.25 .26  0.07 .33
CRPomedian  1.07 .20  0.25 .44  0.32 .17  0.02 .80
Multivariate models adjusted for age, sex, education, born in the United States, depression, history of stroke, history of myocardial infarction, smoking, alcohol, and
missing pattern indicator.
CRP 5 C-reactive protein.
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syndrome (P 5.04), but the difference between the two
groups on the DelRec score was no longer statistically
significant (P 5.17).
Participants with metabolic syndrome with high in-
flammation (median CRP level 3.2 mg/L) had an even
greater multivariate-adjusted decline in 3MS score than
those without high inflammation, with an average score
0.64 lower points per year (P 5.03). After stratification ac-
cording to level of inflammation, there were no significant
differences between those with and without metabolic syn-
drome on the DelRec (Table 2).
The five individual components of metabolic syndrome
were also examined as predictors of cognitive change. At
baseline, participants with elevated fasting blood glucose or
use of antidiabetic medications had lower multivariate ad-
justed scores on the 3MS (Po.001), and those with elevated
triglyceride levels had lower scores on the DelRec (P 5.05)
(Table 3). Only elevated fasting blood glucose or use of
antidiabetic medications was statistically significantly as-
sociated with a lower score on DelRec over time (P.02).
There was a trend-level association with high blood pres-
sure and lower score on the 3MS over time (P 5.05). There
was no association between the other three components
of metabolic syndrome and longitudinal cognitive change
(Table 3), Further stratification according to CRP level did
not appreciably change these results.
DISCUSSION
The rate of cognitive change, as measured using the 3MS,
was worse in older Latinos with metabolic syndrome than
in those without the syndrome. This effect was even more
marked in those with elevated levels of serum markers of
inflammation. These results provide further evidence that
metabolic syndrome and inflammation play a role in cog-
nitive aging.
Previous studies have investigated the individual com-
ponents of metabolic syndrome and risk of cognitive decline
or dementia. Mid- or late-life hypertension,10,11 hyperlip-
idemia,12,13 and diabetes mellitus14–16 have been reported
to increase the risk of developing cognitive impairment due
to vascular disease and Alzheimer’s disease, but few have
assessed the combined effect of multiple cardiovascular risk
factors such as that represented in metabolic syndrome. The
results of the current study suggest that, in elderly Latinos,
the composite measure of metabolic syndrome is a greater
risk for cognitive decline than its individual components,
with the possible exception of impaired glucose control and
high blood pressure.
After multivariate adjustment, the association between
metabolic syndrome and cognitive decline was only evident
for the 3MS, a measure of global cognitive function, and
not for the DelRec, a test of verbal memory. The meaning of
this is not clear but may suggest that the underlying mech-
anism for the association may be due to vascular disease
and not Alzheimer’s disease, in which verbal memory is
classically affected. Because it was not possible to define the
clinical etiology of cognitive decline, there was not an
opportunity to determine whether there is a stronger asso-
ciation between metabolic syndrome and cognitive decline
due to vascular disease than that due to Alzheimer’s disease.
High levels of inflammation increase the risk of the
development of diabetes mellitus and atherosclerosis and
are thought to be a possible mechanism for the adverse
consequences of metabolic syndrome.17,18 In addition,
markers of inflammation have been associated with the
risk of developing dementia and cognitive decline.19,20 It
was found that, in elderly Latinos, those with metabolic
syndrome and high inflammation, as measured according to
CRP, had accelerated cognitive aging. This is consistent
with work in black and white community-dwelling older
people.2 The magnitude of the effect of metabolic syndrome
on those with elevated serum markers of inflammation was
similar in both studies. It may be that the presence of
inflammation indicates disease severity of metabolic
syndrome or that there is a combined effect of metabolic
syndrome and inflammation on cognitive decline.
The strengths of this study include its population-based
design, annual assessment of cognitive tests, and the careful
measurement and subsequent adjustment of possible con-
founders. Several limitations are evident in the study,
including lack of the ability to measure a wide variety
of cognitive domains and to define underlying etiology
of cognitive change. There was thus no opportunity to










Beta P-value Beta P-value Beta P-value Beta P-value
Abdominal obesity  0.31 .55  0.32 .11 0.02 .90  0.06 .25
Hypertriglyceridemia 0.20 .69 0.03 .87 0.27 .05  0.05 .34
Low high-density lipoprotein cholesterol  0.32 .54  0.33 .11  0.15 .32  0.01 .87
High blood pressure  0.01 .98  0.37 .05  0.17 .21  0.03 .54
High fasting blood glucose  1.73 o.001  0.31 .10  0.19 .18  0.12 .02
Note: Mulitvariate models adjusted for time, age, sex, education level, born in the United States, depression, history of stroke, history of myocardial infarction,
smoking, alcohol, and missing pattern indicator.
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determine whether there is a stronger association between
metabolic syndrome and cognitive decline due to vascular
disease than that due to Alzheimer’s disease or vice versa.
Although demographics and several comorbidities, includ-
ing depression, smoking, MI, and stroke, were adjusted for,
it is possible that there is residual confounding. It is con-
ceivable that older people with high CRP levels and met-
abolic syndrome may have worse health outcomes and that
these in turn, contribute to cognitive decline. In addition,
there was only one measure of inflammation, and it would
have been more ideal to have other inflammatory markers
and measured on more than one clinic visit.
This study is important given that risk factors for cog-
nitive decline have been relatively uncharacterized in His-
panic populations. Understanding the health consequences
of metabolic syndrome, especially in those with inflamma-
tion, is crucial in a population that carries a higher inci-
dence and prevalence of this syndrome. Future studies are
needed to examine whether modifications in these risk fac-
tors could lower the risk of developing cognitive decline or
dementia.
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